The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers

Toxicity of Protein Oligomers Is Rationalized by a Function Combining Size and Surface Hydrophobicity

(2014) Benedetta Mannini et al.   ACS Chemical Biology

Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer’s disease

(2014) Kazuma Murakami   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer’s disease

(2014) Frank Dohler et al.   BRAIN

Monoclonal Antibodies against Aβ42 Fibrils Distinguish Multiple Aggregation State Polymorphismsin Vitroand in Alzheimer Disease Brain

(2014) Asa Hatami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Role of Lipid Rafts and GM1 in the Segregation and Processing of Prion Protein

(2014) Laura Botto et al.   PLoS One

Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer’s Disease

(2014) Natalia Salvadores et al.   Cell Reports

Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles

(2013) P Joshi et al.   CELL DEATH AND DIFFERENTIATION

Novel approaches for studying amyloidogenic peptides/proteins

(2013) Marten Beeg et al.   CURRENT OPINION IN PHARMACOLOGY

An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicityin Vivo

(2013) Brian R. Fluharty et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Expression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity

(2013) Luisa Diomede et al.   NEUROBIOLOGY OF DISEASE

Point Mutations in the Transmembrane Region of the Clic1 Ion Channel Selectively Modify Its Biophysical Properties

(2013) Stefania Averaimo et al.   PLoS One

Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases

(2013) Maxime Béland et al.   Prion

Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity

(2013) Andrew J. Nicoll et al.   Nature Communications

Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity

(2012) Ali Reza A. Ladiwala et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Specific Recognition of Biologically Active Amyloid-β Oligomers by a New Surface Plasmon Resonance-based Immunoassay and anin VivoAssay inCaenorhabditis elegans

(2012) Matteo Stravalaci et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Soluble Prion Protein Inhibits Amyloid-β (Aβ) Fibrillization and Toxicity

(2012) Krzysztof Nieznanski et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

(2012) Iryna Benilova et al.   NATURE NEUROSCIENCE

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

(2012) Ji Won Um et al.   NATURE NEUROSCIENCE

The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication

(2011) Ulrike K Resenberger et al.   EMBO JOURNAL

PrPSc-Specific Antibodies with the Ability to Immunodetect Prion Oligomers

(2011) Mourad Tayebi et al.   PLoS One

Alzheimer's Disease: The Challenge of the Second Century

(2011) D. M. Holtzman et al.   Science Translational Medicine

Prion Disease Blood Test Using Immunoprecipitation and Improved Quaking-Induced Conversion

(2011) C. D. Orru et al.   mBio

Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites

(2011) Darragh B. Freir et al.   Nature Communications

Monoclonal Antibody Against the Turn of the 42-Residue Amyloid β-Protein at Positions 22 and 23

(2010) Kazuma Murakami et al.   ACS Chemical Neuroscience

A modified protocol to prepare seed-free starting solutions of amyloid-β (Aβ)1–40 and Aβ1–42 from the corresponding depsipeptides

(2010) Marten Beeg et al.   ANALYTICAL BIOCHEMISTRY

Interaction between Human Prion Protein and Amyloid-β (Aβ) Oligomers

(2010) Shugui Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Generation and Therapeutic Efficacy of Highly Oligomer-Specific  -Amyloid Antibodies

(2010) H. Hillen et al.   JOURNAL OF NEUROSCIENCE

Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies

(2010) Malin Lindhagen-Persson et al.   PLoS One

Synthetic amyloid-  oligomers impair long-term memory independently of cellular prion protein

(2010) C. Balducci et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain

(2009) Floyd Sarsoza et al.   ACTA NEUROPATHOLOGICA

“Click Peptide“: pH-Triggered in Situ Production and Aggregation of Monomer Aβ1-42

(2009) Atsuhiko Taniguchi  et al.   CHEMBIOCHEM

Alzheimer's disease: synaptic dysfunction and Aβ

(2009) Ganesh M Shankar et al.   Molecular Neurodegeneration

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

(2009) Juha Laurén et al.   NATURE

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction

(2009) Jennifer L. Tomic et al.   NEUROBIOLOGY OF DISEASE

Immunopurification of Pathological Prion Protein Aggregates

(2009) Emiliano Biasini et al.   PLoS One

Structural Classification of Toxic Amyloid Oligomers

(2008) Charles G. Glabe   JOURNAL OF BIOLOGICAL CHEMISTRY

Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies

(2008) Emiliano Biasini et al.   JOURNAL OF NEUROCHEMISTRY

Aggregated, Wild-Type Prion Protein Causes Neurological Dysfunction and Synaptic Abnormalities

(2008) R. Chiesa et al.   JOURNAL OF NEUROSCIENCE